Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming
View HTML
Toggle Summary Acceleron Reports Second Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension –
View HTML
Toggle Summary Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results.
View HTML
Toggle Summary Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society
- Mean total muscle volume increases of more than 12% seen in the tibialis anterior – - Company plans to initiate Part 2 of the CMT Phase 2 trial in the third quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
View HTML
Toggle Summary Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 12, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration ( FDA ) has
View HTML
Toggle Summary Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.
View HTML
Toggle Summary Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 5, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K.
View HTML
Toggle Summary Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Results showed significant improvement in red blood cell transfusion independence compared to placebo Safety profile generally consistent with previously published data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass.
View HTML
Toggle Summary Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from
View HTML
Toggle Summary Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
- Clinically meaningful increases in hemoglobin and reductions in red blood cell transfusion burden observed through 36 months – - Top-line results from the BELIEVE Phase 3 trial are on track for the middle of 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2018-- Acceleron Pharma Inc.
View HTML